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Introduction
• The novel SARS-CoV-2 was first 
identified in late 2019.
• COVID Moonshot is an 
international consortium of drug 
designers.
• Moonshot’s X-ray crystallography 
of the Main Protease (Mpro) 
provided a starting fragment.
• Targeting the Mpro would be the 
most effective approach to inhibiting 
the replication of the virus.
The Need for an Oral Antiviral
• While vaccines prevent contraction of the 
virus, oral antiviral medications inhibit the 
replication of the virus after contraction.
• Antiviral medications are complementary to 
vaccines and public health restrictions.
• Vaccines are not 100% effective, especially 
against new strains of the virus.
• Oral antivirals are easier to make and 
distribute.
Methodology: SeeSAR
Fragment x0434 was selected from the Moonshot database of fragments 
that had not yet been analyzed by anyone in the project. The respective 
Protein Data Bank (PDB) code (5QJ5) was entered into SeeSAR.
Left: fragment x0434
Right: protein code 5QJ5
Methodology: SeeSAR
• The fragment was used to design new structures using SeeSAR. 
• The Binding Site mode showed all residues within a 6.5 Angstrom 
radius. All residues were added around the binding site.
• In the Inspirator mode, 502 poses for the binding site with desirable 
binding affinities were generated.
• Molecules were sorted for further analysis.
Methodology: SwissADME
• Fragments were entered into SwissADME program.
• Six main properties were investigated:
◦ Lipinski’s rule (0 violations)
◦ GI absorption (High)
◦ Leadlikeness (0 violations)
◦ PAINS (0 alert)
◦ 5 CYP inhibitors (No)
◦ BBB permeability (Yes)












1 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N N N Y 180869
2 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N Y N Y 321065
3 Yes; 0 violation High Yes 0 alert N N N Y N Y 476753
4 Yes; 0 violation High No; 1 violation: MW<250 0 alert Y N N N N Y 493266
5 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N N N Y 705047
6 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N N N Y 705836
7 Yes; 0 violation High Yes 0 alert N N N N N Y 899362
8 Yes; 0 violation High No; 1 violation: MW<250 0 alert Y N N N N Y 1134899
9 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N N N Y 1539655
10 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N N N Y 1707485
11 Yes; 0 violation High No; 1 violation: MW<250 0 alert N N N N N Y 3870240
Top Three Molecular Structures
beginning fragment x0434
molecule 1 molecule 2 molecule 3
Molecule 3
• no Leadlikeness violations
• drawback: 1 CYP inhibitor
• average binding affinity: 476753 nM
• one-step synthesis route
molecule 
BOILED-egg diagram
◀ a possible 
synthesis route
Molecule 2
• drawbacks: 1 Leadlikeness violation: Mw<250, 1 CYP inhibitor
• average binding affinity: 321065 nM
• one-step synthesis route
molecule 2
BOILED-egg diagram
a possible synthesis route
Molecule 1
• no CYP inhibition
• drawback: 1 Leadlikeness violation: Mw<250
• average binding affinity: 180869 nM
• one-step synthesis route
molecule 1
BOILED-egg diagram
a possible synthesis route
Conclusion
• A fragment was selected from the COVID Moonshot Database, and 
then it was processed in SeeSAR. 
• SwissADME was used to look at various drug-like properties to 
determine which molecules would be most suitable as an oral 
antiviral.
• The top molecules were identified. They will move on to synthesis 
and further collaboration with the COVID Moonshot initiative.
Special thanks to...
Dr. John Thurmond
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